Tag: pancreatic cancer
KRAS-G12D inhibitor shows promise in advanced pancreatic cancer: phase 1b/2 trial results
A phase 1b/2 trial published in Nature Medicine demonstrates that HRS-4642, a targeted KRAS-G12D inhibitor combined with chemotherapy, achieves encouraging…
Targeted therapy combined with chemotherapy shows promise in advanced pancreatic cancer
An investigational targeted therapy combined with standard chemotherapy has shown promising early efficacy in advanced pancreatic cancer, according to data…
Beyond the Breakthrough: Pancreatic Cancer Researchers Warn Real Work Is Just Beginning
A new STAT News commentary warns that while breakthrough pancreatic cancer drugs offer promise, the real work—building healthcare infrastructure, establishing…
Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival
New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly doubling survival times. Clinical trial shows 60% reduction…
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access
Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations. FDA submission planned as five-year pancreatic cancer survival…
Olive Oil Fat Accelerates Pancreatic Cancer While Fish Oil Cuts Risk by Half in Mice
New mouse study reveals oleic acid from olive oil accelerated pancreatic cancer growth while omega-3 fats reduced development by 50%…
Open-Source AI Tool Improves Pancreatic Cancer Vascular Invasion Assessment Across Multiple Centres
New open-source AI system achieves 94.2% accuracy in pancreatic cancer vascular invasion assessment across multiple medical centres. The freely available…
New Drug Daraxonrasib Nearly Doubles Pancreatic Cancer Survival in Phase 3 Trial
Daraxonrasib nearly doubles survival in advanced pancreatic cancer patients with KRAS G12C mutations. The breakthrough targets a previously "undruggable" protein…